Procter & Gamble Health Limited has informed the Exchange regarding Board meeting held on August 01, 2025.
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Procter & Gamble Health reported strong Q1 FY26 results with revenue from operations of ₹33,874 lakhs, up about 19.3% from ₹28,388 lakhs in the same quarter last year. Total income rose to ₹34,277 lakhs from ₹28,601 lakhs. Net profit surged to ₹6,618 lakhs from ₹1,678 lakhs, with basic and diluted EPS at ₹39.87 versus ₹22.27 (before exceptional items). The profit jump is partly inflated because the year-ago quarter had a ₹2,019 lakh one-time charge related to the closure and sale of its Goa injection plant. Costs as a share of revenue fell meaningfully, lifting operating margins significantly year-on-year. Statutory auditor Haribhakti & Co. LLP issued an unmodified limited review report.
Strong quarter for shareholders — revenue growth in the high teens and a sharp jump in profits signal healthy demand and improved cost efficiency. Investors should note last year's base was depressed by a one-off plant-closure charge, so the headline PAT growth overstates underlying improvement, though the underlying business momentum remains clearly positive.